"The LANDSCAPE trial is a valuable addition to the sparse literature on brain metastases and will hopefully motivate and facilitate more research groups to accept the challenge of conducting brain metastasis trials in breast cancer, but also in other tumor types with frequent CNS involvement such as lung cancer and melanoma. A randomized trial of lapatinib/capecitabin versus whole-brain radiotherapy in patients with brain-metastatic HER2-positive breast cancer is warranted and needed to validate the findings of the LANDSCAPE trial." Read the complete ESMO journal club article here.
Study mentioned: Bachelot T, et al. Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study. Lancet Oncol. 2012 Nov 1. [Epub ahead of print] PMID: 23122784
No comments:
Post a Comment